Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Valdecoxib.

Douglas Ormrod1, Keri Wellington, Antona J Wagstaff

  • 1Adis International Limited, Mairangi Bay, Auckland, New Zealand.

Drugs
|September 25, 2002
PubMed
Summary
This summary is machine-generated.

Valdecoxib, a selective cyclo-oxygenase-2 inhibitor, demonstrated superior efficacy over placebo for osteoarthritis, rheumatoid arthritis, and pain relief. It also showed a favorable gastrointestinal safety profile compared to nonselective NSAIDs.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Low-dose doxepin: in the treatment of insomnia.

CNS drugs·2010
Same author

Bevacizumab plus platinum-based chemotherapy: in advanced non-small cell lung cancer.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2009
Same author

Plerixafor: in patients with non-Hodgkin's lymphoma or multiple myeloma.

Drugs·2009
Same author

Sodium picosulfate/magnesium citrate: a review of its use as a colorectal cleanser.

Drugs·2009
Same author

Spotlight on fondaparinux sodium in acute coronary syndromes.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2008
Same author

Fondaparinux sodium: a review of its use in the management of acute coronary syndromes.

American journal of cardiovascular drugs : drugs, devices, and other interventions·2008
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
Same journal

Linerixibat: First Approval.

Drugs·2026
See all related articles

Area of Science:

  • Pharmacology
  • Rheumatology
  • Pain Management

Background:

  • Nonselective nonsteroidal anti-inflammatory drugs (NSAIDs) carry risks of gastrointestinal complications.
  • Selective cyclo-oxygenase-2 (COX-2) inhibitors offer a potential alternative with improved gastrointestinal safety.
  • Valdecoxib is a selective COX-2 inhibitor investigated for its efficacy and safety.

Purpose of the Study:

  • To evaluate the efficacy of valdecoxib in treating osteoarthritis, rheumatoid arthritis, and pain.
  • To compare valdecoxib's efficacy and safety against placebo and other NSAIDs.
  • To assess valdecoxib's impact on platelet function and gastrointestinal erosions.

Main Methods:

  • Ten large, well-controlled, randomized trials involving 203 to 1089 participants.

Related Experiment Videos

  • Valdecoxib dosages ranged from 1.25 to 40 mg daily.
  • Comparisons included placebo, naproxen, ibuprofen, diclofenac, oxycodone/paracetamol, and rofecoxib.

    • Main Results:

    • Valdecoxib was significantly more effective than placebo for osteoarthritis, rheumatoid arthritis, primary dysmenorrhea pain, and postsurgical analgesia.
    • Valdecoxib demonstrated comparable efficacy to naproxen for osteoarthritis and rheumatoid arthritis.
    • Valdecoxib did not significantly affect platelet function or bleeding times and reduced gastroduodenal erosions compared to ibuprofen and diclofenac.

    Conclusions:

    • Valdecoxib is an effective treatment for osteoarthritis, rheumatoid arthritis, and various pain conditions.
    • Valdecoxib offers a favorable gastrointestinal safety profile compared to traditional NSAIDs.
    • Valdecoxib provides significant pain relief with a generally well-tolerated adverse event profile similar to placebo.